Edgewise Therapeutics, Inc. (EWTX)
NASDAQ • Healthcare
Last close at October 2, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 32 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Edgewise Therapeutics’ preliminary results for the second fiscal quarter of 2026 showed a wider loss than expected, with EPS of -$0.53 trailing the -$0.47 estimate, -13%, when it reported on August 6, 2026. Net income was a loss of roughly $57.3 million, down 58.7% year over year from a loss of about $36.1 million a year ago, while EPS declined 55.9% from -$0.34. Operating income came in at a loss of about $61.9 million, and the company posted negative operating cash flow of roughly $43.5 million. For the next period, consensus calls for EPS of -$0.55 on revenue of $129.2 million.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on small-molecule medicines for muscle disease. In qualitative terms, it is an early-stage healthcare developer, and its lead program is EDG-5506, an orally administered compound being studied for dystrophinopathies and other genetically defined muscle conditions.
Today's Snapshot
EWTX closed 2.3% above yesterday's close, while its sector was flat.
Trading Volume
Below 10d avg (1.9M)
1.3M
vs S&P 500 Today
Outperforming Market
+1.49%
Updated: October 2, 2026 at 20:08 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$34.40 - $42.08Buy
- RSI (14)46.47Neutral
- Stochastic %K (14, 3, 3)23.17Neutral
- MACD Level (12, 26)-0.77Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.